Security key
690469101
Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID)
CUSIP: 690469101
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 147,000,742
- Total 13F value
- $395,504,576
- Share change
- +31,884,678
- Put/Call ratio
- 67%
- SEC-reported price per share
- $2.69
- Number of holders
- 129
- Value change
- +$88,183,470
- Number of buys
- 76
- Number of sells
- 45
- Shares outstanding
- 187,450,569
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
129
Top holders
10
OVID full security history
Ownership snapshot
Full 13F holder table
Ovid Therapeutics Inc. SEC filings
Ovid Therapeutics Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of OVID - Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TAKEDA PHARMACEUTICAL CO LTD
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 12%
13D/G row: TAKEDA PHARMACEUTICAL CO LTD
Showing 1-6 of 15 holder rows.
Quick read
TAKEDA PHARMACEUTICAL CO LTD leads the comparable SEC ownership view at 12%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TAKEDA PHARMACEUTICAL CO LTD's linked filing trail.
Comparable ownership
Top 5
TAKEDA PHARMACEUTICAL CO LTD
12%
Janus Henderson Group Ltd.
10%
RA CAPITAL MANAGEMENT, L.P.
9.9%
Sirenia Capital Management LP
9.9%
Affinity Asset Advisors, LLC
7.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TAKEDA PHARMACEUTICAL CO LTD |
13D/G
3/4/5
Takeda Pharmaceutical Company Limited · 10%+ Owner
|
12%
|
$11,680,055
8,781,996 shares
|
$0 | 08 Dec 2025 |
| Janus Henderson Group Ltd. |
13F
13D/G
Company · JANUS HENDERSON GROUP PLC
|
10%
from 13D/G
|
$23,731,510
10,714,000 shares
|
— | 31 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
Company
|
9.9%
|
$53,369,510
19,549,271 shares
|
+$17,170,433 | 30 Jun 2026 |
| Sirenia Capital Management LP |
13D/G
|
9.9%
|
$51,930,239
18,031,333 shares
|
$0 | 31 Mar 2026 |
| Affinity Asset Advisors, LLC |
13D/G
13F
Company
|
7.9%
|
$41,342,377
15,143,728 shares
|
-$1,342,494 | 30 Jun 2026 |
| EVENTIDE ASSET MANAGEMENT, LLC |
13D/G
13F
Company
|
6.3%
|
$32,247,418
11,812,241 shares
|
-$2,624,447 | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
129
Shares
147,000,742
Rows available
129
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
103
Q2 2026 holders
129
Holder diff
26
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|